BioAge Labs (NASDAQ:BIOA) Given Buy Rating at Roth Capital

BioAge Labs (NASDAQ:BIOA)‘s stock had its “buy” rating restated by stock analysts at Roth Capital in a note issued to investors on Wednesday, Benzinga reports. They presently have a $25.00 price objective on the stock. Roth Capital’s price objective would indicate a potential upside of 175.48% from the stock’s current price.

A number of other equities analysts have also commented on BIOA. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, July 21st. Needham & Company LLC decreased their price objective on BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a report on Friday, July 31st. Jefferies Financial Group set a $21.00 target price on BioAge Labs in a research report on Friday, July 31st. Wall Street Zen downgraded BioAge Labs from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, BTIG Research reiterated a “buy” rating and issued a $40.00 price target on shares of BioAge Labs in a research report on Tuesday. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $36.57.

BioAge Labs Stock Performance

Shares of NASDAQ:BIOA traded down $0.33 during midday trading on Wednesday, hitting $9.07. 226,552 shares of the stock were exchanged, compared to its average volume of 692,858. The business’s 50-day moving average price is $15.89 and its 200 day moving average price is $17.67. BioAge Labs has a 12 month low of $4.68 and a 12 month high of $25.95. The stock has a market capitalization of $416.54 million, a price-to-earnings ratio of -3.82 and a beta of 0.94.

BioAge Labs (NASDAQ:BIOA) last posted its earnings results on Wednesday, August 5th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.07. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. The business had revenue of $2.45 million for the quarter. As a group, sell-side analysts expect that BioAge Labs will post -2.45 EPS for the current year.

Institutional Investors Weigh In On BioAge Labs

Hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. bought a new position in shares of BioAge Labs during the 3rd quarter worth approximately $27,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of BioAge Labs by 85.6% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after acquiring an additional 5,976 shares in the last quarter. Walleye Capital LLC acquired a new position in shares of BioAge Labs during the 2nd quarter valued at $64,000. Bank of America Corp DE lifted its position in shares of BioAge Labs by 46.3% during the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after acquiring an additional 3,517 shares during the period. Finally, Legal & General Group Plc bought a new position in BioAge Labs during the second quarter worth $84,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.